The molecule costs $129. The brand costs $1,865. The difference isn't chemistry.

The folk story is that BPC-157 is a generalized "healing peptide." The mechanism research disagrees. BPC-157 upregulates VEGFR2-mediated angiogenesis and activates endothelial nitric-oxide synthase (eNOS) through the Akt pathway — that's the actual lever.

It's not magic. It's targeted vascular and connective-tissue repair. Which means it's predictably useful for tendon, ligament, and gut-mucosa injuries — and predictably less useful for things that don't depend on those pathways.

This matters for protocol design. If you understand the mechanism, you can predict the response window (4–8 weeks for tendon, 7–14 days for gut) and stop chasing applications it was never built for.

Most cosmetic copy treats the copper tripeptide GHK-Cu as a topical antioxidant. The 2014 gene-profiling work tells a different story. GHK-Cu modulates the expression of more than 4,000 human genes — and shifts the pattern toward a younger transcriptomic baseline.

The most striking signal: 47 DNA-repair genes get upregulated, and only 5 get downregulated. That's a 9:1 ratio, and it's the kind of broad-spectrum profile you'd expect from a bioregulator, not a skincare ingredient.

Implication: GHK-Cu's most interesting research applications aren't cosmetic. They're cellular. The skin and hair effects are downstream side-effects of something doing real work upstream.

From 2022 to early 2025 there was a clean price arbitrage: compounded semaglutide ran ~$129/mo while branded Wegovy listed at ~$1,865/mo retail without insurance. People who knew the gap saved thousands.

That window closed. The 503A compounding pathway shut April 22, 2025; the 503B pathway closed May 22, 2025. Novo Nordisk responded by introducing $199–$349/mo self-pay tiers, collapsing the spread for people who can navigate it.

The new edge isn't price — it's protocol. Knowing dose-response curves, escalation timing, and side-effect mitigation now produces more outcome variance than where you source the compound. The savings moved from your supplier to your knowledge.